Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2Phase 3 Interventional

Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT01383148

Public ClinicalTrials.gov record NCT01383148. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Study identification

NCT ID
NCT01383148
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Transgene
Industry
Enrollment
222 participants

Conditions and interventions

Interventions

  • TG4010 Biological
  • placebo Drug

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2012
Primary completion
Jun 30, 2015
Completion
Jun 30, 2016
Last update posted
Jan 4, 2017

2012 – 2016

United States locations

U.S. sites
12
U.S. states
9
U.S. cities
12
Facility City State ZIP Site status
Mayo Clinic Arizona Scottsdale Arizona 85259
Cotton O'Neil Clinical Research Center Topeka Kansas 66606
University of Louisville Hospital Louisville Kentucky 40402
Massachusetts General Hospital Cambridge Maryland 2114
Oncology/Hematology P.C. Rockville Maryland 20850
Washington University St Louis Missouri 63110
Highlands Oncology Group Fayetteville North Carolina 72703
Signal Point Clinical Research Center Middletown Ohio 45042
ProMedica Health System Inc Toledo Ohio 43606
Abington Hematology Oncology Associates Inc Willow Grove Pennsylvania 19090
Texas Oncology, P.A. - Abilene (South) Abilene Texas 79606
Mary Crowley Medical Research Center Dallas Texas 75246

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01383148, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 4, 2017 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01383148 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →